GoDaddy Billionaire Owner Supports Use of Psychedelics as Treatment for PTSD

April 22, 2022 10:48:32

Over the past couple of years, there has been increased interest in psychedelics as alternative treatments for mental disorders. With most mental health medications causing side effects such as muscle spasms, nausea, constipation and loss of sex drive, there has been a push for safer alternative medications.

Studies show that psychedelics have the potential to treat mental disorders, including post-traumatic stress disorder (PTSD), major depressive disorder, anorexia nervosa and alcohol-use disorder.

Mental health conditions take nearly 8 million lives every year and cost the world billions of dollars in lost productivity. According to the National Institute of Mental Health (NIMH), one in five Americans is living with a mental health condition.

Bob Parsons, the billionaire owner of GoDaddy, the world’s largest web host domain registrar, is a Vietnam war veteran who has benefited a great deal from psychedelic treatments. Now he is throwing his weight behind the push for psychedelic treatments and donating millions of dollars to psychedelic research.

Decades after he left the rice paddies of South Vietnam, Parsons was still haunted by the war. Although he couldn’t quite place what the problem was, he knew that he was different from the young man who grew up poor in Boston. Post-traumatic stress disorder left him with a hair-trigger temper, exacerbated his antisocial tendencies and changed his personality. The condition most certainly cost him two marriages, he says.

In 2018, he underwent multiple therapy sessions with psychedelics under the watchful eye of a trained therapist. His treatment program involved controlled psychedelics including psilocybin, DMT and LSD. Parsons was feeling better and more relaxed within days, he says. Although the psychedelic-assisted treatment wasn’t pleasant, it alleviated his PTSD symptoms and left him feeling more relaxed and at ease than he had been in years.

He is now an ardent supporter of psychedelic treatments for post-traumatic stress disorder. He and his wife have donated $5 million to the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai where therapists are educated on MDMA-assisted therapies.

Parsons donated a further $2 million to the Multidisciplinary Association for Psychedelic Studies (MAPS). Results from the organization’s clinical trial using MDMA-assisted treatments for trauma found that nearly 70% of participants who went through the treatment alongside psychotherapy no longer qualified for a PTSD diagnosis after two months of treatment.

PayPal’s billionaire founder Peter Thiel has also put money into the burgeoning psychedelics market. He recently invested in Atai Life Sciences, a German-biotech company that owns several companies which are running various clinical trials using psychedelic molecules.

Different psychedelic compounds have so much therapeutic promise that some companies, such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), have gone as far as earmarking significant amounts of money toward the development of psilocybin vaporization technology to add other administration options to the choices available once psychedelic therapies get regulatory approval.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.